PT  - JOURNAL ARTICLE
AU  - Tang, Jinyi
AU  - Zeng, Cong
AU  - Cox, Thomas M.
AU  - Li, Chaofan
AU  - Son, Young Min
AU  - Cheon, In Su
AU  - Wu, Yue
AU  - Behl, Supriya
AU  - Taylor, Justin J.
AU  - Chakaraborty, Rana
AU  - Johnson, Aaron J.
AU  - Shiavo, Dante N
AU  - Utz, James P.
AU  - Reisenauer, Janani S.
AU  - Midthun, David E.
AU  - Mullon, John J.
AU  - Edell, Eric S.
AU  - Alameh, Mohamad G.
AU  - Borish, Larry
AU  - Kaplan, Mark H.
AU  - Weissman, Drew
AU  - Kern, Ryan
AU  - Hu, Haitao
AU  - Vassallo, Robert
AU  - Liu, Shan-Lu
AU  - Sun, Jie
TI  - Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccination
AID  - 10.1101/2022.01.26.22269659
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.26.22269659
4099  - http://medrxiv.org/content/early/2022/01/27/2022.01.26.22269659.short
4100  - http://medrxiv.org/content/early/2022/01/27/2022.01.26.22269659.full
AB  - SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S-specific total and neutralizing antibody (Ab) responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19 vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing Ab against D614G, Delta and Omicron in the BAL compared to COVID-19 convalescents, despite robust S-specific Ab responses in the blood. Further, mRNA vaccination induced significant circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using an animal immunization model, we demonstrate that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing Ab responses, especially against SARS-CoV-2 Omicron; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing Ab response, not only against the ancestral virus but also the Omicron variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during re-infection, but offer limited protection against breakthrough infection, especially by Omicron. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by Omicron and future variants.Competing Interest StatementJ.S. is a consultant for the Teneofour company, which does not directly involve with this project.Funding StatementAI147394, AG047156 and AG069264 to J.S.; AI147394S1 to J.S., an anonymous private donor to The Ohio State University and NCI U54CA260582, NIH R01 AI150473. to S.-L.L., M.H.K. was supported by AI057459; H.H. was supported by AI147903 and AI157852Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Mayo Clinic Institutional Review Boards, IRB protocol # 19-012187.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors